Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aktis Oncology, Inc. (AKTS)

Aktis Oncology appoints Glenn Gormley to board; Helen Kim and Oleg Nodelman to resign

Neutral Impact 3 of 5 leadership Written later

Aktis Oncology appointed Glenn Gormley, MD, PhD, a former Daiichi Sankyo executive, as a director effective April 15, 2026, and named him co-chair of a newly created Science and Technology Committee. Directors Helen S. Kim and Oleg Nodelman will leave the board effective May 20, 2026, and the company said their resignations are not due to any disagreement with the company.

Key points

  • Gormley appointed as a Class I director effective April 15, 2026, with a term expiring at the 2027 annual meeting; he is co-chair of the Science and Technology Committee with Ken Herrmann, MD, PhD
  • Non-employee director pay: $45,000 per year for board service and $15,000 per year for committee co-chair service, prorated for the year
  • Gormley granted an option on April 15, 2026 to buy up to 37,866 shares of common stock, vesting in equal annual installments over three years
  • Helen S. Kim and Oleg Nodelman resign from the board and all committees effective May 20, 2026

The filing

CompanyAktis Oncology, Inc. (AKTS)
Form8-K, current report
Filed with the SECApr 16, 2026, 4:01 PM ET
Accession number0001193125-26-158944

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.